Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,529 JPY | +0.39% | +2.51% | +8.83% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.83% | 3.62B | B+ | ||
+26.68% | 681B | C+ | ||
+21.85% | 556B | B | ||
-4.89% | 361B | C+ | ||
+17.15% | 325B | B- | ||
+5.35% | 285B | C+ | ||
+13.68% | 235B | B+ | ||
+3.65% | 199B | B- | ||
-11.12% | 189B | A+ | ||
-4.10% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4536 Stock
- Ratings Santen Pharmaceutical Co., Ltd.